Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.
Psoriasis vulgaris is a common, chronic inflammatory skin disease with a prevalence of 1.5-2% in Western industrialized countries. A relevant percentage of patients suffer from moderate-to-severe psoriasis and experience a significant reduction in quality of life. The choice of an adequate therapy could help to prevent disease and exacerbation of comorbidity, which could increase quality of life, avoid hospitalization and avoid reduction of working days. The present guidelines are focused on the initiation and management of systemic therapies in cases of moderate-to-severe plaque-type psoriasis in adults to optimize treatment response, adherence and quality of life. This first version of the Swiss S1 guidelines presents therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of dermatologists in Switzerland.
Department of Dermatology, Zurich University Hospital, Zurich, Switzerland.
Antonios G A
AG
Kolios
Nikhil
N
Yawalkar
Mark
M
Anliker
Wolf-Henning
WH
Boehncke
Luca
L
Borradori
Curdin
C
Conrad
Michel
M
Gilliet
Peter
P
Häusermann
Peter
P
Itin
Emmanuel
E
Laffitte
Carlo
C
Mainetti
Lars E
LE
French
Alexander A
AA
Navarini
D017255:Acitretin / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D003880:Dermatology / Q000592:standards*; D005650:Fumarates / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D012955:Societies, Medical; D013557:Switzerland; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D001685:Biological Factors; D005650:Fumarates; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D013792:Thalidomide; D016572:Cyclosporine; D017255:Acitretin; C505730:apremilast